The Big Phar­ma axe: Mer­ck cuts chikun­gun­ya vax, Bris­tol My­ers drops Cy­tomX-part­nered pro­gram, and more

As fourth quar­ter earn­ings come in, Big Phar­mas are dis­clos­ing changes to their pipelines dur­ing their in­vestor calls, and some­times more qui­et­ly in pre­sen­ta­tion ap­pen­dices.

Mer­ck dropped its chikun­gun­ya vac­cine can­di­date, which com­plet­ed a Phase II study. Mer­ck ac­quired the vac­cine through its pur­chase of Themis Bio­science in 2020. In de­vel­op­ing a vac­cine for chikun­gun­ya, a mos­qui­to-borne virus, Val­ne­va is the fron­trun­ner, as it sub­mit­ted its vac­cine to the FDA at the end of De­cem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.